Sarcopenia and NMIBC Prognosis Study
ConditionBladder Cancer Cell Transitional
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGeneral Hospital Sveti Duh
About this trial
The goal of this observational study is to evaluate whether body composition abnormalities (sarcopenia, myosteatosis, and obesity) and nutritional status influence the risk of recurrence and progression in adult patients with non-muscle-invasive bladder cancer (NMIBC). The main questions it aims to answer are:
Do sarcopenia, myosteatosis, obesity, or malnutrition increase the likelihood of NMIBC recurrence and progression?
Can clinical, laboratory, and CT-derived body composition parameters serve as predictive biomarkers that improve individualized risk stratification?
Participants will undergo routine clinical and radiologic assessments, including:
* completion of the SARC-F and NRS nutritional screening questionnaires * anthropometric measurements (BMI, waist circumference) * laboratory evaluation including serum albumin and testosterone * CT-based assessment of skeletal muscle index (SMI) and muscle density (SMD) * standard TURBT and structured follow-up with cystoscopy, cytology, imaging, and clinical evaluations to document recurrence and progression.
Eligibility criteria
Qualifiers
Adults aged 18 years or older
Histologically confirmed non-muscle-invasive bladder cancer (NMIBC) (Ta, T1, or CIS)
Scheduled for transurethral resection of bladder tumor (TURBT) as part of standard care
Able to undergo CT imaging required for assessment of skeletal muscle index (SMI) and skeletal muscle density (SMD)
Disqualifiers
Low-risk NMIBC, as defined by clinical guidelines
Muscle-invasive bladder cancer (≥ T2) at diagnosis
Expected survival less than 3 months
Contraindications to CT imaging (e.g., severe renal dysfunction, contrast allergy if contrast required)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
150 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov